

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 May 2018

At the annual general meeting (the “AGM”) of China Pioneer Pharma Holdings Limited (the “Company”) held on 15 May 2018, voting on all the proposed resolutions as set out in the notice of the AGM dated 13 April 2018 was taken by poll.

As at the date of the AGM, the total number of issued shares of the Company was 1,296,699,000 shares, which was the total number of shares entitling the holders to attend and vote on the resolutions proposed at the AGM. There were no restrictions on any shareholders of the Company casting votes on any of the proposed resolutions at the AGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor of the Company for the year ended 31 December 2017.	979,033,156 98.73%	12,560,000 1.27%
2.	To re-elect Mr. Li Xinzhou as an executive director of the Company.	945,935,191 95.40%	45,657,965 4.60%
3.	To re-elect Mr. Xu Zhonghai as an independent non-executive director of the Company.	977,786,156 98.61%	13,807,000 1.39%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
4.	To re-elect Mr. Lai Chanshu as an independent non-executive director of the Company.	977,786,156 98.61%	13,807,000 1.39%
5.	To authorise the board of directors of the Company to fix the remuneration of the directors of the Company.	971,328,156 97.96%	20,265,000 2.04%
6.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the board of directors of the Company to fix its remuneration.	977,933,156 98.62%	13,660,000 1.38%
7.	To give a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the number of issued shares of the Company as at the date of this resolution.	893,679,000 90.13%	97,914,156 9.87%
8.	To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the number of issued shares of the Company as at the date of this resolution.	979,033,156 98.73%	12,560,000 1.27%
9.	To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 7 to issue shares by adding the number of shares repurchased under ordinary resolution no. 8.	897,479,352 90.51%	94,113,804 9.49%

As more than 50% of votes were cast in favour of each of the resolutions, all of the above ordinary resolutions were approved by the shareholders of the Company.

By order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Shanghai, 15 May 2018

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou and Mr. ZHU Mengjun as executive directors, Mr. WANG Yinping and Mr. WU Mijia as non-executive directors and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive directors.